- Home
- HYFM vs BTAI Comparison
HYFM vs BTAI Comparison
Compare HYFM & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- BTAI
- Stock Information
- Founded
- HYFM 1977
- BTAI 2017
- Country
- HYFM United States
- BTAI United States
- Employees
- HYFM N/A
- BTAI N/A
- Industry
- HYFM Industrial Machinery/Components
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- HYFM Industrials
- BTAI Health Care
- Exchange
- HYFM Nasdaq
- BTAI Nasdaq
- Market Cap
- HYFM 31.3M
- BTAI 28.7M
- IPO Year
- HYFM 2020
- BTAI 2018
- Fundamental
- Price
- HYFM $0.55
- BTAI $0.58
- Analyst Decision
- HYFM Hold
- BTAI Strong Buy
- Analyst Count
- HYFM 2
- BTAI 4
- Target Price
- HYFM $0.70
- BTAI $5.00
- AVG Volume (30 Days)
- HYFM 105.8K
- BTAI 409.5K
- Earning Date
- HYFM 11-07-2024
- BTAI 11-14-2024
- Dividend Yield
- HYFM N/A
- BTAI N/A
- EPS Growth
- HYFM N/A
- BTAI N/A
- EPS
- HYFM N/A
- BTAI N/A
- Revenue
- HYFM $200,158,000.00
- BTAI $2,403,000.00
- Revenue This Year
- HYFM N/A
- BTAI $247.03
- Revenue Next Year
- HYFM $3.48
- BTAI $88.16
- P/E Ratio
- HYFM N/A
- BTAI N/A
- Revenue Growth
- HYFM N/A
- BTAI 131.50
- 52 Week Low
- HYFM $0.43
- BTAI $0.51
- 52 Week High
- HYFM $1.20
- BTAI $4.89
- Technical
- Relative Strength Index (RSI)
- HYFM 28.99
- BTAI 44.09
- Support Level
- HYFM $0.55
- BTAI $0.62
- Resistance Level
- HYFM $0.62
- BTAI $0.72
- Average True Range (ATR)
- HYFM 0.05
- BTAI 0.07
- MACD
- HYFM -0.01
- BTAI -0.01
- Stochastic Oscillator
- HYFM 0.06
- BTAI 0.00
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.